SIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 22.8% in November

SIGA Technologies, Inc. (NASDAQ:SIGA) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 3,530,000 shares, a drop of 22.8% from the October 31st total of 4,570,000 shares. Approximately 8.7% of the company’s shares are sold short. Based on an average daily trading volume, of 584,300 shares, the short-interest ratio is currently 6.0 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SIGA. Larson Financial Group LLC purchased a new position in SIGA Technologies in the third quarter valued at approximately $30,000. DekaBank Deutsche Girozentrale bought a new stake in shares of SIGA Technologies in the second quarter valued at $40,000. EP Wealth Advisors LLC bought a new stake in shares of SIGA Technologies in the third quarter valued at $82,000. XTX Topco Ltd purchased a new position in shares of SIGA Technologies during the 3rd quarter valued at $85,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of SIGA Technologies by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,727 shares of the company’s stock worth $93,000 after acquiring an additional 5,372 shares during the period. 55.40% of the stock is owned by institutional investors.

SIGA Technologies Price Performance

Shares of SIGA Technologies stock opened at $7.36 on Friday. The firm has a market cap of $525.50 million, a price-to-earnings ratio of 6.13 and a beta of 0.89. SIGA Technologies has a one year low of $4.26 and a one year high of $12.83. The stock’s 50-day moving average is $6.99 and its 200 day moving average is $7.85.

SIGA Technologies (NASDAQ:SIGA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.02 earnings per share for the quarter. SIGA Technologies had a net margin of 49.33% and a return on equity of 49.06%. The firm had revenue of $10.01 million for the quarter. On average, sell-side analysts expect that SIGA Technologies will post 1.04 EPS for the current fiscal year.

SIGA Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.